NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

PSYCHIATRY RESEARCH-NEUROIMAGING, published by Elsevier Ireland Ltd, stands at the intersection of neuroscience, psychiatry, and medical imaging, specializing in the latest advancements in neuroimaging techniques and their applications in psychiatric research. With a robust history since 1990, this esteemed journal features original research, reviews, and case studies that contribute significantly to the understanding of brain function in mental health disorders. Holding a notable Impact Factor and classified in Q2 for the fields of Neuroscience and Psychiatry and Q1 for Radiology, it serves as a vital resource for scholars and practitioners seeking to advance their knowledge in these domains. The journal is indexed in major databases, enhancing visibility and accessibility for global researchers. While it currently does not follow an open-access model, its reputable standing in Scopus ranks, alongside its targeted scope, makes it indispensable for those invested in neuroimaging research and its implications in psychiatry.

Middle East Current Psychiatry (MECPsych), published by SpringerNature, is a prominent open-access journal dedicated to advancing the field of psychiatry and mental health in the Middle East and beyond. Since its establishment in 2011, MECPsych has aimed to disseminate high-quality research, reviews, and reports that capture recent developments in psychiatric science, clinical practice, and public health considerations in mental well-being. With an impact factor reflective of its growing influence and classified in the Q3 quartile for Psychiatry and Mental Health, the journal offers invaluable insights backed by rigorous peer review processes. Operating under an open access model since 2019, MECPsych ensures that its articles are freely accessible to a global readership, enhancing the visibility and application of research findings. As part of its ongoing commitment to enriching understanding in the field, MECPsych also encourages submissions that explore the unique cultural, societal, and economic factors influencing mental health across the region. This approach not only supports researchers, professionals, and students in their pursuit of knowledge but also fosters a collaborative dialogue among mental health stakeholders in the Middle East and around the world.

Psychiatry Investigation is a prominent, peer-reviewed journal published by the Korean Neuropsychiatric Association, focusing on advancements in the fields of psychiatry and mental health. With an ISSN of 1738-3684 and an E-ISSN of 1976-3026, this journal has steadily gained recognition within the academic community since its inception in 2006. Spanning a dynamic spectrum of research topics, it aims to disseminate innovative findings and facilitate discussions that contribute to the understanding and treatment of psychiatric disorders. As evidenced by its current Scopus rankings—positioned in the Q2 category for Psychiatry and Mental Health and the Q3 category for Biological Psychiatry—the journal is committed to maintaining high scholarly standards and impactful research contributions. Although fully open access is not available, the relevance of its content ensures that it remains a critical resource for researchers, clinicians, and students alike, furthering knowledge and practices in the field of mental health.

Alpha Psychiatry, published by AVES, stands at the forefront of mental health research and psychiatric advancements. With a commitment to disseminating high-quality and impactful studies, this journal serves as a critical platform for scholars, clinicians, and students interested in exploring the complexities of psychiatric disorders and treatment methodologies. Although the impact factor and specific scope details are still evolving, Alpha Psychiatry is dedicated to fostering interdisciplinary dialogue and promoting innovative research that tackles contemporary challenges in the field of psychiatry. As an open-access journal, it ensures that research is widely accessible, enhancing knowledge transfer and collaboration within the global scientific community. Located in Istanbul, Turkiye, the journal proudly represents a rich academic tradition, aiming to contribute significantly to the global discourse on mental health.

Frontiers in Psychiatry is a leading journal dedicated to advancing research within the field of psychiatry and mental health. Published by FRONTIERS MEDIA SA, the journal has established a commendable reputation since its inception, reflected in its Q1 status in the 2023 Psychiatry and Mental Health category and a robust ranking of 142 out of 567 in the Scopus database. With an open access model initiated in 2009, Frontiers in Psychiatry aims to disseminate high-quality research to a global audience, fostering collaboration and innovation among researchers, clinicians, and students alike. The journal covers a broad spectrum of topics, including neurobiology, psychosocial factors, treatments, and public health implications of mental disorders, ensuring comprehensive representation of contemporary psychiatric science. Located in Lausanne, Switzerland, and running until 2024, the journal not only emphasizes the importance of mental health research but also encourages interdisciplinary discourse, making it an essential resource for anyone invested in the well-being of individuals and communities alike.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, a premier academic journal published by TAYLOR & FRANCIS LTD, stands at the forefront of interdisciplinary research in the fields of Biological Psychiatry, Psychiatry, and Mental Health. Based in the United Kingdom, this esteemed journal (ISSN: 1562-2975; E-ISSN: 1814-1412) has become increasingly influential since its inception in 2000, with a remarkable impact factor that reflects its high-quality research contributions. The journal is consistently ranked in the Q1 and Q2 categories across various relevant indices, demonstrating its reputation for excellence within the academic community. With Scopus rankings placing it in the top 20th percentile for Psychiatry and Mental Health, the WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY serves as a vital resource for researchers, professionals, and students seeking to further their understanding of the intricate relationship between biological processes and psychiatric phenomena. Despite being a traditional access journal, it possesses a robust scope that encompasses groundbreaking studies, reviews, and advancements in the understanding of mental health disorders, underlining its importance as a key reference in the advancement of psychiatric science and therapeutic practices.

JAMA Psychiatry, published by the American Medical Association, stands as a leading peer-reviewed journal in the fields of psychiatry and mental health, featuring an impressive impact factor that reflects its significance in advancing research and clinical practice. With an ISSN of 2168-622X and an E-ISSN of 2168-6238, this journal operates on a comprehensive access model that allows for the dissemination of vital research findings to a global audience. Since its inception in 2013, JAMA Psychiatry has consistently ranked in the top quartile (Q1) in both the Medicine (miscellaneous) and Psychiatry and Mental Health categories, with a remarkable Scopus rank of #4 out of 567, placing it in the 99th percentile. Addressed from its headquarters in Chicago, Illinois, the journal's objectives encompass the publication of original clinical research, innovative treatment strategies, and insightful reviews that enrich the understanding of psychiatric disorders. By bridging the gap between research and real-world application, JAMA Psychiatry remains an essential resource for researchers, clinicians, and students dedicated to improving mental health outcomes.

Behavioural Pharmacology is a distinguished academic journal published by Lippincott Williams & Wilkins, focusing on the intricate relationship between pharmacology, psychiatry, and behavioral science. With an ISSN of 0955-8810 and an E-ISSN of 1473-5849, this journal serves as a vital platform for researchers and professionals dedicated to exploring the pharmacological mechanisms underlying behavior and mental health. Operating with a robust track record since its inception in 1992, it has established itself in the academic community, as reflected by its Q3 rankings in both the pharmacology and psychiatry categories for 2023. Additionally, the journal holds a credible position in Scopus rankings, with a percentile ranking indicative of significant contributions to the fields of pharmacology and psychiatry. Aimed at advancing knowledge and disseminating research in the behavioral pharmacology domain, this journal is an essential resource for students, researchers, and clinical professionals seeking to stay at the forefront of this rapidly evolving field. While it is not an open access journal, the rich content and research findings published here continue to foster collaboration and innovation within the community, making it a crucial reference point for current and future studies.

Biological Psychiatry: Global Open Science is a prestigious journal published by Elsevier, focusing on the field of psychiatry and mental health. With an ISSN of 2667-1743 and an E-ISSN of the same number, this journal has quickly established itself as a vital resource for researchers, clinicians, and students seeking to enhance their understanding of biological underpinnings in psychiatric disorders. Launched in 2021, the journal has achieved a remarkable Q1 ranking in the Psychiatry and Mental Health category by 2023, underscoring its commitment to high-quality, impactful research. Although currently operating without an open access model, it aims to provide a platform for innovative studies and breakthroughs that advance the global discourse in mental health. The journal is especially relevant for those interested in the latest developments, as it is aligned with the growing emphasis on evidence-based practice and the integration of biological findings into psychiatric care. With an H-Index reflecting its ongoing influence and relevance, Biological Psychiatry: Global Open Science is poised to become a cornerstone publication for those dedicated to the advancement of mental health research.